Altimmune Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 59

Employees

  • Stock Symbol
  • ALT

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $4.97
  • (As of Wednesday Closing)

Altimmune General Information

Description

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Contact Information

Website
www.altimmune.com
Formerly Known As
ImmuneFocus, Vaxin Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 910 Clopper Road
  • Suite 201-S
  • Gaithersburg, MD 20878
  • United States
+1 (240)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 910 Clopper Road
  • Suite 201-S
  • Gaithersburg, MD 20878
  • United States
+1 (240)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Altimmune Stock Performance

As of 23-Apr-2025, Altimmune’s stock price is $4.97. Its current market cap is $383M with 77M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.97 $4.85 $3.55 - $11.16 $383M 77M 2.49M -$1.34

Altimmune Financials Summary

As of 31-Dec-2024, Altimmune has a trailing 12-month revenue of $20K.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 375,202 375,202 464,459 608,069
Revenue 20 20 426 (68)
EBITDA (102,886) (102,886) (95,263) (87,272)
Net Income (95,059) (95,059) (88,447) (84,713)
Total Assets 139,306 139,306 210,640 206,928
Total Debt 1,681 1,681 671 1,124
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Altimmune Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Altimmune‘s full profile, request access.

Request a free trial

Altimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic dise
Drug Discovery
Gaithersburg, MD
59 As of 2024

Indianapolis, IN
 

Melbourne, Australia
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Altimmune Competitors (55)

One of Altimmune’s 55 competitors is Apexian Pharmaceuticals, a Venture Capital-Backed company based in Indianapolis, IN.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN
Mesoblast Corporation Melbourne, Australia
Hansa Biopharma Corporation Lund, Sweden
NexImmune Formerly VC-backed Gaithersburg, MD
Arcus Biosciences Formerly VC-backed Hayward, CA
You’re viewing 5 of 55 competitors. Get the full list »

Altimmune Patents

  • 226

    Total Documents Applications and Grants

  • Total Patents Families

  • 113

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

Altimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3167833-A1 Coronavirus immunogenic compositions and uses thereof Pending 14-Feb-2020
US-11382968-B2 Coronavirus immunogenic compositions and uses thereof Active 14-Feb-2020
AU-2021220971-A1 Coronavirus immunogenic compositions and uses thereof Inactive 14-Feb-2020
US-20220072121-A1 Coronavirus immunogenic compositions and uses thereof Active 14-Feb-2020
US-20210260180-A1 Coronavirus immunogenic compositions and uses thereof Inactive 14-Feb-2020 A61K39/215
To view Altimmune’s complete patent history, request access »

Altimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Altimmune Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Altimmune‘s full profile, request access.

Request a free trial

Altimmune Acquisitions (3)

Altimmune’s most recent deal was a Merger/Acquisition with Spitfire Pharma for . The deal was made on 08-Jul-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Spitfire Pharma 08-Jul-2019 Merger/Acquisition Drug Discovery
Pharmathene 04-May-2017 Merger/Acquisition Pharmaceuticals
Immune Targeting Systems 17-Feb-2015 Merger/Acquisition Biotechnology
To view Altimmune’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Altimmune ESG

Risk Overview

Risk Rating

Updated October, 22, 2024

37.14 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Biotechnology

Subindustry

of 371

Rank

Percentile

To view Altimmune’s complete esg history, request access »

Altimmune FAQs

  • When was Altimmune founded?

    Altimmune was founded in 1997.

  • Where is Altimmune headquartered?

    Altimmune is headquartered in Gaithersburg, MD.

  • What is the size of Altimmune?

    Altimmune has 59 total employees.

  • What industry is Altimmune in?

    Altimmune’s primary industry is Drug Discovery.

  • Is Altimmune a private or public company?

    Altimmune is a Public company.

  • What is Altimmune’s stock symbol?

    The ticker symbol for Altimmune is ALT.

  • What is the current stock price of Altimmune?

    As of 23-Apr-2025 the stock price of Altimmune is $4.97.

  • What is the current market cap of Altimmune?

    The current market capitalization of Altimmune is $383M.

  • What is Altimmune’s current revenue?

    The trailing twelve month revenue for Altimmune is $20K.

  • Who are Altimmune’s competitors?

    Apexian Pharmaceuticals, Mesoblast, Hansa Biopharma, NexImmune, and Arcus Biosciences are some of the 55 competitors of Altimmune.

  • What is Altimmune’s annual earnings per share (EPS)?

    Altimmune’s EPS for 12 months was -$1.34.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »